Krystal Biotech (KRYS) Could Be 40% Overvalued As KB801 News Tests Its Price

KB801Negative

AI Analysis

Summary

An analysis article suggests Krystal Biotech (KRYS) may be overvalued by approximately 40%, with KB801 news being cited as a price test driver. The article provides valuation commentary without disclosing specific catalyst dates or clinical trial outcomes.

Importance:4/10

Sentiment:

-0.60

valuationstock_analysisKB801

Related Companies

$KRYS

Read the original article

Published by yahoo_finance on July 30, 2026 8:07 AM

Read Original